GlaxoSmithKline PLC (UK) Performance
| GSK Stock | 1,340 3.50 0.26% |
The company retains a Market Volatility (i.e., Beta) of 0.26, which attests to not very significant fluctuations relative to the market. As returns on the market increase, GlaxoSmithKline PLC's returns are expected to increase less than the market. However, during the bear market, the loss of holding GlaxoSmithKline PLC is expected to be smaller as well. At this point, GlaxoSmithKline PLC has a negative expected return of -0.3%. Please make sure to check out GlaxoSmithKline PLC's total risk alpha, potential upside, and the relationship between the standard deviation and maximum drawdown , to decide if GlaxoSmithKline PLC performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days GlaxoSmithKline PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's technical and fundamental indicators remain rather sound which may send shares a bit higher in December 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Forward Dividend Yield 0.0446 | Payout Ratio 0.0037 | Last Split Factor 4:5 | Forward Dividend Rate 0.6 | Ex Dividend Date 2024-11-14 |
1 | GSK CEO Is Trying to Move Past Overhang of Zantac Litigation on Shares - Bloomberg | 09/25/2024 |
2 | Pfizer Wins London Court Battle, GSKs Respiratory Syncytial Virus Vaccine Patents Invalidated - Yahoo Finance | 10/07/2024 |
| GlaxoSmithKline PLC dividend paid on 10th of October 2024 | 10/10/2024 |
3 | This Dividend Stock With a 4 percent Yield Is a Buy After Some Positive News - Morningstar | 10/21/2024 |
4 | GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study - Zacks Investment Research | 11/20/2024 |
| Begin Period Cash Flow | 3.4 B |
GlaxoSmithKline |
GlaxoSmithKline PLC Relative Risk vs. Return Landscape
If you would invest 163,232 in GlaxoSmithKline PLC on August 31, 2024 and sell it today you would lose (29,182) from holding GlaxoSmithKline PLC or give up 17.88% of portfolio value over 90 days. GlaxoSmithKline PLC is generating negative expected returns and assumes 1.2304% volatility on return distribution over the 90 days horizon. Simply put, 10% of stocks are less volatile than GlaxoSmithKline, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
GlaxoSmithKline PLC Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for GlaxoSmithKline PLC's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as GlaxoSmithKline PLC, and traders can use it to determine the average amount a GlaxoSmithKline PLC's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2436
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GSK |
Estimated Market Risk
| 1.23 actual daily | 10 90% of assets are more volatile |
Expected Return
| -0.3 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.24 actual daily | 0 Most of other assets perform better |
Based on monthly moving average GlaxoSmithKline PLC is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GlaxoSmithKline PLC by adding GlaxoSmithKline PLC to a well-diversified portfolio.
GlaxoSmithKline PLC Fundamentals Growth
GlaxoSmithKline Stock prices reflect investors' perceptions of the future prospects and financial health of GlaxoSmithKline PLC, and GlaxoSmithKline PLC fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GlaxoSmithKline Stock performance.
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.0724 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 67.69 B | ||||
| Shares Outstanding | 4.08 B | ||||
| Price To Book | 3.92 X | ||||
| Price To Sales | 1.75 X | ||||
| Revenue | 30.33 B | ||||
| Gross Profit | 19.92 B | ||||
| EBITDA | 9.14 B | ||||
| Net Income | 4.93 B | ||||
| Total Debt | 18.02 B | ||||
| Book Value Per Share | 3.43 X | ||||
| Cash Flow From Operations | 6.77 B | ||||
| Earnings Per Share | 0.61 X | ||||
| Total Asset | 59.01 B | ||||
| Retained Earnings | 7.24 B | ||||
About GlaxoSmithKline PLC Performance
By analyzing GlaxoSmithKline PLC's fundamental ratios, stakeholders can gain valuable insights into GlaxoSmithKline PLC's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if GlaxoSmithKline PLC has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if GlaxoSmithKline PLC has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
GlaxoSmithKline PLC is entity of United Kingdom. It is traded as Stock on LSE exchange.Things to note about GlaxoSmithKline PLC performance evaluation
Checking the ongoing alerts about GlaxoSmithKline PLC for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for GlaxoSmithKline PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| GlaxoSmithKline PLC generated a negative expected return over the last 90 days | |
| On 10th of October 2024 GlaxoSmithKline PLC paid 0.15 per share dividend to its current shareholders | |
| Latest headline from news.google.com: GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study - Zacks Investment Research |
- Analyzing GlaxoSmithKline PLC's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether GlaxoSmithKline PLC's stock is overvalued or undervalued compared to its peers.
- Examining GlaxoSmithKline PLC's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating GlaxoSmithKline PLC's management team can have a significant impact on its success or failure. Reviewing the track record and experience of GlaxoSmithKline PLC's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of GlaxoSmithKline PLC's stock. These opinions can provide insight into GlaxoSmithKline PLC's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for GlaxoSmithKline Stock analysis
When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |